Cadent Therapeutics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 25

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $770M

Cadent Therapeutics General Information

Description

Operator of a precision neuroscience company intended to develop drugs focused on psychiatric diseases. The company's firm develops small molecule therapeutics targeting the NMDA (N-Methyl-D-Aspartate) receptor to treat spinocerebellar ataxia, essential tremor, neuropsychiatric disorders, schizophrenia, and other cognitive and neuropsychiatric disorders, thereby enabling hospitals to restore brain rhythms and improve outcomes in patients living with movement, mood, and cognitive disorders.

Contact Information

Formerly Known As
Mnemosyne Pharmaceuticals, Luc Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 60 Hamilton Street
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Discovery
Acquirer
Vertical(s)
Corporate Office
  • 60 Hamilton Street
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cadent Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 31-Mar-2021 $770M Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 29-Apr-2020 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A1) 03-Mar-2017 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 21-Jun-2013 Completed Product Development
2. Buyout/LBO $700K Completed Startup
1. Seed Round 14-Nov-2011 $700K $700K Completed Startup
To view Cadent Therapeutics’s complete valuation and funding history, request access »

Cadent Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A1
Series A 31,790,600 $0.001000 6% $0.51 $0.51 1x $0.51 24.93%
To view Cadent Therapeutics’s complete cap table history, request access »

Cadent Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a precision neuroscience company intended to develop drugs focused on psychiatric diseases. The company's fi
Drug Discovery
Cambridge, MA
25 As of 2020

Lexington, MA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cadent Therapeutics Competitors (38)

One of Cadent Therapeutics’s 38 competitors is Voyager Therapeutics, a Formerly VC-backed company based in Lexington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Voyager Therapeutics Formerly VC-backed Lexington, MA
CervoMed Formerly VC-backed Boston, MA
NeuroNascent Venture Capital-Backed Clarksville, MD
Cognition Therapeutics Formerly VC-backed New York, NY
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 38 competitors. Get the full list »

Cadent Therapeutics Patents

Cadent Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022204337-A1 Novel cyclopenta[c]pyrrol negative allosteric modulators of nr2b Inactive 26-Mar-2021
WO-2022204336-A1 Novel cyclopental[c]pyrrol negative allosteric modulators of nr2b Inactive 26-Mar-2021
WO-2020086456-A1 Crystalline forms of potassium channel modulators Inactive 22-Oct-2018
WO-2020086136-A2 Heteroaromatic nmda receptor modulators and uses thereof Inactive 03-Aug-2018
WO-2020086136-A3 Heteroaromatic nmda receptor modulators and uses thereof Inactive 03-Aug-2018 C07D487/04
To view Cadent Therapeutics’s complete patent history, request access »

Cadent Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cadent Therapeutics Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Access Industries PE/Buyout Minority
Atlas Venture Venture Capital Minority
Clal Biotechnology Industries Venture Capital Minority
Cowen Healthcare Investments Venture Capital Minority
Qiming Venture Partners USA Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Cadent Therapeutics Acquisitions (1)

Cadent Therapeutics’s most recent deal was a Merger/Acquisition with Ataxion. The deal was made on 06-Mar-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ataxion 06-Mar-2017 Merger/Acquisition Drug Discovery
To view Cadent Therapeutics’s complete acquisitions history, request access »

Cadent Therapeutics FAQs

  • When was Cadent Therapeutics founded?

    Cadent Therapeutics was founded in 2010.

  • Where is Cadent Therapeutics headquartered?

    Cadent Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Cadent Therapeutics?

    Cadent Therapeutics has 25 total employees.

  • What industry is Cadent Therapeutics in?

    Cadent Therapeutics’s primary industry is Drug Discovery.

  • Is Cadent Therapeutics a private or public company?

    Cadent Therapeutics is a Private company.

  • What is the current valuation of Cadent Therapeutics?

    The current valuation of Cadent Therapeutics is .

  • What is Cadent Therapeutics’s current revenue?

    The current revenue for Cadent Therapeutics is .

  • How much funding has Cadent Therapeutics raised over time?

    Cadent Therapeutics has raised $68.3M.

  • Who are Cadent Therapeutics’s investors?

    Access Industries, Atlas Venture, Clal Biotechnology Industries, Cowen Healthcare Investments, and Qiming Venture Partners USA are 5 of 6 investors who have invested in Cadent Therapeutics.

  • Who are Cadent Therapeutics’s competitors?

    Voyager Therapeutics, CervoMed, NeuroNascent, Cognition Therapeutics, and Neurona Therapeutics are some of the 38 competitors of Cadent Therapeutics.

  • When was Cadent Therapeutics acquired?

    Cadent Therapeutics was acquired on 31-Mar-2021.

  • Who acquired Cadent Therapeutics?

    Cadent Therapeutics was acquired by Novartis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process